Journal of mucopolysaccharidosis and rare diseases

Association for Research of MPS and Rare Diseases (뮤코다당증연구학회)
권호 표지
DOI QR코드

DOI QR Code

An Update on Prader-Willi Syndrome with Diabetes Mellitus

  • Lee, Ji-Eun (Department of Pediatrics, Inha University Hospital, Inha University School of Medicine)
  • Received : 2016.12.12
  • Accepted : 2016.12.20
  • Published : 2016.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Prader-Willi syndrome (PWS) often develops type 2 diabetes mellitus (T2DM) related to severe obesity. The prevalence of T2DM in adults with PWS (7-20%) exceeds greatly the prevalence in the general population (5-7%). It is uncommon for pre-pubertal children with PWS to develop overt diabetes or glucose intolerance. GH therapy and genotype did not influence the development of altered glucose metabolism. It has been assumed that T2DM in PWS develops as a consequence of morbid obesity and concomitant insulin resistance. However recent studies suggest the relationship between morbid obesity and T2DM development is more complex and appears to differ in PWS subjects compared to non-PWS subjects. PWS patients had relatively lower fasting insulin levels and increased adiponectin levels compared with BMI-matched obese control despite of similar levels of leptin. So PWS children may be protected to some extent form of obesity-associated insulin resistance. Although there's no data, it seems logical to approach diabetes management including weight loss and increased exercise, using similar pharmacological agents as with non-PWS obesity-related diabetes such as metformin or thiazolidinedione, with the introduction of insulin as required. On the other hand, several recent T2DM in PWS case reports suggest favorable outcomes using Glucagon-like peptide 1 (GLP-1) analog with regard to ghrelin reduction, control of glucose and appetite, weight loss and pre-prandial insulin secretion. The role of GLP-1 agonist therapy is promising, but has not yet been fully elucidated.

Keywords

References

  1. Whittington JE, Holland AJ, Webb T, Butler JV, Clarke DJ, Boer H. Population prevalence and estimated birth incidence and mortality rate for peple with Prader-Willi Syndrome in on UK Health Region. J Med Genet 2001;38:792-8. https://doi.org/10.1136/jmg.38.11.792
  2. Scerif M, Goldstone AP, Korbonits M. Ghrelin in obeisty and endocrine diseases. Mol cell Endocrinol 2011;96:E225-32.
  3. Dezaki K, Hosoda H, Kakei M, Hashiguchi S, Watanabe M, Kangawa K, et al. Endogenous ghrelin in pancratic islets resticts insulin release by attenuating Ca2+ signaling in betacells: implication in the glycemic control in redents. Diabetes 2004;53:3142-51. https://doi.org/10.2337/diabetes.53.12.3142
  4. Goldstone AP, Thomas EL, Brynes AE, Bell JD, Frost G, Saeed N, et al. Visceral adipose tissue and metabolic complications of oesity are reduced in Prader-Willi syndrome female aduls: evidence for novel influences on body fat distribution. J Clin Endocinol Metab 2001;86:4330-8. https://doi.org/10.1210/jcem.86.9.7814
  5. Talebizadeh Z, Butler MG. Insulin resistance and obesityreleated factors in Prader-Willi syndrome: comparison with obese subjects. Clin Genet 2005;67:230-9.
  6. Lacroix D, Moutel S, Coupaye M, Huvenne H, Faucher P, Pelloux V, et al. Metabolic and adipose tissue signatures in adults with Prader-Willi syndrome: a model of extreme adiposity. J Clin Endocrinol Metab 2015;100:850-9. https://doi.org/10.1210/jc.2014-3127
  7. Purtell L, Viardot A, Sze L, Loughnan G, Steinbeck K, Sainsbury A, et al. Postprandial metabolism in adults with Prader-Willi syndrome. Obesity (silver Spring) 2015;23:1159-65. https://doi.org/10.1002/oby.21041
  8. Berthoud HR, Powley TL. Morphology and distribution of efferent vagal innervation of rat pancreas as revealed with anterograde transport of Dil. Brain Res 1991;553:336-41. https://doi.org/10.1016/0006-8993(91)90846-N
  9. Irizarry KA, Miller M, Freemark M, Haqq AM. Prader Willi syndrome: genetics, metabolomics, hormonal function, and new approaches to therapy. Adv Pediatr 2016;63:47-77. https://doi.org/10.1016/j.yapd.2016.04.005
  10. Butler JV, Whittington JE, Holland AJ, Boer H, Clarke C, Webb T. Prevalence of, and risk factors for, physical illhealth in people with Prader-Willi syndrome: a populationbased study. Dev Med Child Neurol 2002;44:248-55. https://doi.org/10.1017/S001216220100202X
  11. Laurier V, Lapeyrade A, Copet P, Demeer G, Silvie M, Bieth E, et al. Medical, psychological and social features in a large cohort of adults with Prader-Willi syndrome: experience from a dedicated centre in France. J Intellect Disabil Res 2015;59:411-21. https://doi.org/10.1111/jir.12140
  12. Diene G, Mimoun E, Feigerlova E, Caula S, Molinas C, Grandjean H, et al. Endocrine disorders in children with Prader-Willi syndrome-data from 142 children of the French database. Horm Res Paediatr 2010;74:121-8. https://doi.org/10.1159/000313377
  13. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728-42. https://doi.org/10.1038/nrendo.2012.140
  14. Sze L, Purtell L, Jenkins A, Loughnan G, Smith E, Herzog H, et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrionl Metab 2011;96:E1314-9. https://doi.org/10.1210/jc.2011-0038
  15. Fintini D, Grugni G, Brufani C, Bocchini S, Cappa M, Crino A. Use of GLP-1 receptor agonists in Prader-Willi Syndrome: report of six cases. Diabetes Care 2014;37:e76-7. https://doi.org/10.2337/dc13-2575

Cited by

  1. Hypothalamic neuropeptides and neurocircuitries in Prader Willi syndrome vol.33, pp.7, 2016, https://doi.org/10.1111/jne.12994